Cytokinetics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cytokinetics (CYTK).

Price Target Range — 9 Quarters

Analyst Consensus — 21 Analysts

3S.Buy

17Buy

1Hold

Consensus RatingBuy# Analysts21Avg. Consensus PT$99Upside to Avg. PT+61.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$112→$113
Aug 31, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$140
Aug 13, 2026	Barclays	Emily Field	PT Raise	Overweight	$95→$110
Aug 13, 2026	JP Morgan	Tessa Romero	PT Raise	Overweight	$97→$103
Aug 10, 2026	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$106→$112
Aug 7, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$117→$112
Aug 7, 2026	Citizens	Jason N. Butler	PT Raise	Market Outperform	$105→$110
Aug 7, 2026	Needham	Serge Belanger	PT Raise	Buy	$102→$112
Jul 7, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$119→$117
Jun 29, 2026	UBS	Ashwani Verma	Upgrade	Neutral→Buy	$69→$115
Jun 24, 2026	Mizuho	Salim Syed	PT Raise	Outperform	$100→$118
Jun 17, 2026	Needham	Serge Belanger	Maintained	Buy	$102
May 19, 2026	Citigroup	Eric Joseph	Initiate	Buy	$99
May 12, 2026	JP Morgan	Tessa Romero	PT Raise	Overweight	$92→$97
May 11, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$136→$140
May 7, 2026	Wells Fargo	Yanan Zhu	PT Raise	Overweight	$95→$105
May 6, 2026	Stifel	James Condulis	PT Raise	Buy	$98→$108
May 6, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$90→$103
May 6, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$101→$119
May 5, 2026	Needham	Serge Belanger	PT Raise	Buy	$85→$102

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $113

RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the price target from $112 to $113.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $140 price target.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $110

Barclays analyst Emily Field maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $95 to $110.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $103

JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $97 to $103.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $112

Truist Securities analyst Srikripa Devarakonda maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $106 to $112.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $112

RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $117 to $112.

Benzinga Newsdesk

Cytokinetics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Cytokinetics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $113

PRO
HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target

PRO
Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $110

PRO
JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $103

PRO
Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $112

PRO
RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $112

People Also Watch

People Also Watch

Cytokinetics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Cytokinetics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $113

PROHC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target

PROBarclays Maintains Overweight on Cytokinetics, Raises Price Target to $110

PROJP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $103

PROTruist Securities Maintains Buy on Cytokinetics, Raises Price Target to $112

PRORBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $112

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $113

PRO
HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target

PRO
Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $110

PRO
JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $103

PRO
Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $112

PRO
RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $112